Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 59.67 Billion KRW | 54.44% |
| 2022 | 38.63 Billion KRW | 206.79% |
| 2021 | 12.59 Billion KRW | 83.73% |
| 2020 | 6.85 Billion KRW | -50.95% |
| 2019 | 13.97 Billion KRW | 33.65% |
| 2018 | 10.45 Billion KRW | -25.16% |
| 2017 | 13.97 Billion KRW | -33.16% |
| 2016 | 20.9 Billion KRW | -6.73% |
| 2015 | 22.41 Billion KRW | 26.27% |
| 2014 | 17.75 Billion KRW | 49.25% |
| 2013 | 11.89 Billion KRW | -46.54% |
| 2012 | 22.24 Billion KRW | 4.88% |
| 2011 | 21.21 Billion KRW | 59.12% |
| 2010 | 13.33 Billion KRW | -71.18% |
| 2009 | 46.25 Billion KRW | 32.55% |
| 2008 | 34.9 Billion KRW | -6.21% |
| 2007 | 37.21 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 55.84 Billion KRW | 0.13% |
| 2024 Q1 | 55.77 Billion KRW | -6.53% |
| 2023 Q1 | 45.19 Billion KRW | 16.96% |
| 2023 Q3 | 54.92 Billion KRW | 22.69% |
| 2023 Q2 | 44.76 Billion KRW | -0.94% |
| 2023 FY | 59.67 Billion KRW | 54.44% |
| 2023 Q4 | 59.67 Billion KRW | 8.64% |
| 2022 Q1 | 28.97 Billion KRW | 130.08% |
| 2022 Q2 | 24.66 Billion KRW | -14.89% |
| 2022 Q3 | 28.44 Billion KRW | 15.33% |
| 2022 Q4 | 38.63 Billion KRW | 35.84% |
| 2022 FY | 38.63 Billion KRW | 206.79% |
| 2021 FY | 12.59 Billion KRW | 83.73% |
| 2021 Q1 | 10.17 Billion KRW | 48.39% |
| 2021 Q2 | 11.05 Billion KRW | 8.7% |
| 2021 Q3 | 5.81 Billion KRW | -47.37% |
| 2021 Q4 | 12.59 Billion KRW | 116.44% |
| 2020 Q3 | 12.01 Billion KRW | -15.69% |
| 2020 Q2 | 14.25 Billion KRW | 2.61% |
| 2020 Q1 | 13.89 Billion KRW | -0.6% |
| 2020 FY | 6.85 Billion KRW | -50.95% |
| 2020 Q4 | 6.85 Billion KRW | -42.96% |
| 2019 Q2 | 17.5 Billion KRW | 8.83% |
| 2019 Q3 | 8.27 Billion KRW | -52.73% |
| 2019 Q4 | 13.97 Billion KRW | 68.92% |
| 2019 FY | 13.97 Billion KRW | 33.65% |
| 2019 Q1 | 16.08 Billion KRW | 53.79% |
| 2018 Q2 | 12.42 Billion KRW | 81.96% |
| 2018 Q4 | 10.45 Billion KRW | -28.7% |
| 2018 FY | 10.45 Billion KRW | -25.16% |
| 2018 Q1 | 6.82 Billion KRW | -51.14% |
| 2018 Q3 | 14.66 Billion KRW | 18.06% |
| 2017 Q3 | 11.97 Billion KRW | -10.45% |
| 2017 Q4 | 13.97 Billion KRW | 16.73% |
| 2017 FY | 13.97 Billion KRW | -33.16% |
| 2017 Q1 | 18.76 Billion KRW | -10.22% |
| 2017 Q2 | 13.36 Billion KRW | -28.78% |
| 2016 Q4 | 20.9 Billion KRW | -13.31% |
| 2016 FY | 20.9 Billion KRW | -6.73% |
| 2016 Q3 | 24.11 Billion KRW | -0.31% |
| 2016 Q2 | 24.19 Billion KRW | 14.89% |
| 2016 Q1 | 21.05 Billion KRW | -6.06% |
| 2015 Q2 | 25.1 Billion KRW | 11.16% |
| 2015 Q4 | 22.41 Billion KRW | -24.68% |
| 2015 Q3 | 29.75 Billion KRW | 18.53% |
| 2015 Q1 | 22.58 Billion KRW | 27.24% |
| 2015 FY | 22.41 Billion KRW | 26.27% |
| 2014 Q1 | 14.98 Billion KRW | 26.02% |
| 2014 Q2 | 18.37 Billion KRW | 22.6% |
| 2014 FY | 17.75 Billion KRW | 49.25% |
| 2014 Q4 | 17.75 Billion KRW | -13.64% |
| 2014 Q3 | 20.55 Billion KRW | 11.86% |
| 2013 Q3 | 23.44 Billion KRW | -21.1% |
| 2013 Q4 | 11.89 Billion KRW | -49.28% |
| 2013 Q2 | 29.72 Billion KRW | 40.71% |
| 2013 FY | 11.89 Billion KRW | -46.54% |
| 2013 Q1 | 21.12 Billion KRW | -5.05% |
| 2012 FY | 22.24 Billion KRW | 4.88% |
| 2012 Q4 | 22.24 Billion KRW | -5.22% |
| 2012 Q3 | 23.47 Billion KRW | -4.62% |
| 2012 Q2 | 24.6 Billion KRW | 14.82% |
| 2012 Q1 | 21.43 Billion KRW | 1.04% |
| 2011 FY | 21.21 Billion KRW | 59.12% |
| 2011 Q2 | 19.26 Billion KRW | 5.1% |
| 2011 Q1 | 18.32 Billion KRW | 37.49% |
| 2011 Q4 | 21.21 Billion KRW | 13.4% |
| 2011 Q3 | 18.7 Billion KRW | -2.9% |
| 2010 Q1 | 44.75 Billion KRW | -3.24% |
| 2010 Q4 | 13.33 Billion KRW | 6.68% |
| 2010 Q3 | 12.49 Billion KRW | -72.43% |
| 2010 Q2 | 45.32 Billion KRW | 1.27% |
| 2010 FY | 13.33 Billion KRW | -71.18% |
| 2009 Q1 | 42.85 Billion KRW | 22.8% |
| 2009 Q4 | 46.25 Billion KRW | 14.83% |
| 2009 FY | 46.25 Billion KRW | 32.55% |
| 2009 Q2 | 40.98 Billion KRW | -4.38% |
| 2009 Q3 | 40.28 Billion KRW | -1.7% |
| 2008 Q2 | 35.68 Billion KRW | -3.74% |
| 2008 Q4 | 34.9 Billion KRW | -2.92% |
| 2008 FY | 34.9 Billion KRW | -6.21% |
| 2008 Q3 | 35.94 Billion KRW | 0.74% |
| 2008 Q1 | 37.07 Billion KRW | -0.37% |
| 2007 Q1 | 80.95 Billion KRW | 0.0% |
| 2007 Q4 | 37.21 Billion KRW | -48.82% |
| 2007 Q3 | 72.7 Billion KRW | -0.33% |
| 2007 Q2 | 72.94 Billion KRW | -9.9% |
| 2007 FY | 37.21 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -577.942% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 89.568% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 80.804% |
| HANDOK Inc. | 283.45 Billion KRW | 78.948% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -197.298% |
| Yuhan Corporation | -69.18 Billion KRW | 186.251% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 69.232% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 1719.024% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 88.477% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 283.998% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 21.144% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -61.994% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 27.685% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -137.666% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -577.942% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 137.332% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 70.303% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 65.091% |
| JW Holdings Corporation | 480.68 Billion KRW | 87.586% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 63.742% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -50672.977% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 61.344% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -2437.904% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -159.437% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 65.895% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -14.814% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -577.942% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 62.302% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 83.34% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 61.344% |
| Yuhan Corporation | -69.18 Billion KRW | 186.251% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 56.119% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 86.095% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 61.344% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 48.661% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -263.311% |
| CKD Bio Corp. | 143.29 Billion KRW | 58.356% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 48.586% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 348.005% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 233.398% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -2437.904% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 85.887% |
| Boryung Corporation | 187.72 Billion KRW | 68.212% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 183.065% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 21.144% |
| JW Lifescience Corporation | 26.09 Billion KRW | -128.718% |